Weight & Metabolism
Cagrisema
Choose an option
Select the amount per vial, then choose a package size.
Amount per vial
Package size
Your estimate includes a flat $65 shipping charge and an 8% transaction fee on the product subtotal. No payment is collected here.
Overview
High-dose CagriSema for advanced dual-hormone metabolic research. Maximum combined amylin/GLP-1 agonism for studying synergistic satiety, gastric emptying, and metabolic regulation.
- Selected variation
- Cagrisema 10mg+10mg
- Amount per vial
- 20mg
- Intended use
- Laboratory research only
- Route of administration
- Subcutaneous injection
Research information
Cagrisema is a combination research compound consisting of Cagrilintide and Semaglutide, designed to investigate multi-target metabolic regulation. It is studied for its potential to impact glucose metabolism and satiety signaling in laboratory settings. Evidence for this combination is currently limited to ongoing preclinical and clinical research trials.
For laboratory research only. Not for human or animal consumption. Catalog information is not medical advice or a claim of therapeutic benefit.